Nexavar fails combo trial, but keeps liver cancer crown

By Tracy Staton Nexavar plus Tarceva did not equate to improved survival for liver cancer patients in a new trial. But that doesn’t mean Nexavar is losing its edge. In fact, ...

WHO endorses use of HIV medicines for prevention

By Ransdell Pierson (Reuters) – The World Health Organization has endorsed using HIV medicines among people who do not have the infection but are at high risk of getting it and ...

J&J Appeals $1.2 Billion Arkansas Risperdal Ruling

By Jef Feeley Johnson & Johnson (JNJ) appealed an Arkansas judge’s decision to fine the drugmaker $1.2 billion over what state officials said was a misleading marketing campaign ...

Pfizer Loses Prempro Ruling, Must Pay $10.4 Million

By Jef Feeley Pfizer (PFE) Inc. must pay $10.4 million in damages to a woman who blamed the company’s Prempro menopause drug for her breast cancer, an appeals court said. Jurors ...

Pertussis Rates Raise Questions About Vaccine

By Kristina Fiore, Staff Writer, MedPage Today There have been more than 18,000 cases of whooping cough in the U.S. so far in 2012 — that’s twice as many as last year this ...

Mylan, Somaxon settle insomnia drug suit

Mylan can sell generic version starting Jan. 1, 2020, or earlier BY ALARIC DEARMENT PITTSBURGH — Mylan has settled a patent litigation suit filed by Somaxon Pharmaceutical concerning ...

Pfizer Wins Lyrica Patent Ruling

By PETER LOFTUS A U.S. judge has upheld the validity of patents covering Pfizer Inc.’s PFE +0.67% pain drug Lyrica, preserving market U.S. exclusivity for one of the company’s ...

J&J Penalty May Total $2.2 Billion

Settlement Over Risperdal Marketing Would Include $400 Million Criminal Fine By JONATHAN D. ROCKOFF and JOANN S. LUBLIN Johnson & Johnson JNJ +0.61% and federal prosecutors ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS